Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis

Einhorn, 1985, Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population, Cancer, 55, 2019, 10.1002/1097-0142(19850501)55:9<2019::AID-CNCR2820550932>3.0.CO;2-2

Carney, 2002, A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?, Gynecologic Oncology, 84, 36, 10.1006/gyno.2001.6460

Maggino, 1994, Prospective multicenter study on CA 125 in postmenopausal pelvic masses, Gynecologic Oncology, 54, 117, 10.1006/gyno.1994.1179

Roman, 1997, Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer, Obstetrics and Gynecology, 89, 493, 10.1016/S0029-7844(97)00075-6

McDonald, 2010, Predicting risk of malignancy in adnexal masses, Obstetrics and Gynecology, 115, 687, 10.1097/AOG.0b013e3181d44053

Buamah, 2000, Benign conditions associated with raised serum CA-125 concentration, Journal of Surgical Oncology, 75, 264, 10.1002/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q

Jacobs, 1989, The CA 125 tumour-associated antigen: a review of the literature, Human Reproduction, 4, 1, 10.1093/oxfordjournals.humrep.a136832

Moore, 2008, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecologic Oncology, 108, 402, 10.1016/j.ygyno.2007.10.017

Drapkin, 2005, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Research, 65, 2162, 10.1158/0008-5472.CAN-04-3924

Whiting, 2003, The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews, BMC Medical Research Methodology, 3, 25, 10.1186/1471-2288-3-25

DerSimonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Huedo-Medina, 2006, Assessing heterogeneity in meta-analysis: Q statistic or I2 index?, Psychological Methods, 11, 193, 10.1037/1082-989X.11.2.193

Dinnes, 2005, A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy, Health Technology Assessment, 9, 1, 10.3310/hta9120

Andersen, 2010, Use of a symptom index, CA125, and HE4 to predict ovarian cancer, Gynecologic Oncology, 116, 378, 10.1016/j.ygyno.2009.10.087

Havrilesky, 2008, Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence, Gynecologic Oncology, 110, 374, 10.1016/j.ygyno.2008.04.041

Moore, 2009, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, Gynecologic Oncology, 112, 40, 10.1016/j.ygyno.2008.08.031

Park, 2011, Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases, Clinical Biochemistry, 44, 884, 10.1016/j.clinbiochem.2011.04.011

Yurkovetsky, 2010, Development of a multimarker assay for early detection of ovarian cancer, Journal of Clinical Oncology, 28, 2159, 10.1200/JCO.2008.19.2484

Hellstrom, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Research, 63, 3695

Montagnana, 2009, The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass, Journal of Clinical Laboratory Analysis, 23, 331, 10.1002/jcla.20340

Van Gorp, 2011, HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm, British Journal of Cancer, 104, 863, 10.1038/sj.bjc.6606092

Molina, 2011, HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases, Tumour Biology, 32, 1087, 10.1007/s13277-011-0204-3

Partheen, 2011, Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass, Journal of Gynecologic Oncology, 22, 244, 10.3802/jgo.2011.22.4.244

Huhtinen, 2009, Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts, British Journal of Cancer, 100, 1315, 10.1038/sj.bjc.6605011

Nolen, 2010, Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass, Gynecologic Oncology, 117, 440, 10.1016/j.ygyno.2010.02.005

Abdel-Azeez, 2010, HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses, Asian Pacific Journal of Cancer Prevention, 11, 111

Jacob, 2011, No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting, Gynecologic Oncology, 121, 487, 10.1016/j.ygyno.2011.02.022

Chang, 2011, Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma, International Journal of Gynecological Cancer, 21, 852, 10.1097/IGC.0b013e31821a3726

Park, 2012, Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer, International Journal of Cancer, 130, 1136, 10.1002/ijc.26129

Holcomb, 2011, Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women, American Journal of Obstetrics and Gynecology, 205, 358e1, 10.1016/j.ajog.2011.05.017

Medeiros, 2009, Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 142, 99, 10.1016/j.ejogrb.2008.08.011

Moore, 2010, Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass, American Journal of Obstetrics and Gynecology, 203, 228e1, 10.1016/j.ajog.2010.03.043